Promedior Presents Preclinical Data at American Association for Study of Liver Diseases Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect
11/7/2011 8:01:35 AM
MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011) on Sunday, November 6, 2011, in San Francisco, CA. In a poster entitled “Serum amyloid P attenuates hepatic fibrosis in mice by inhibiting the activation of fibrocytes and hepatic stellate cells,” Promedior and collaborators from the University of California, San Diego School of Medicine presented data which highlight the efficacy and utility of Pentraxin-2 in suppressing fibrosis and providing a strong hepatoprotective effect in two independent models of liver fibrosis.
comments powered by